Cationic antimicrobial peptides and biogenic silver nanoparticles kill mycobacteria without eliciting DNA damage and
Soumitra Mohanty1, Prajna Jena, Ranjit Mehta
1School of Biotechnology, KIIT University, Bhubaneswar, Orissa, India.
Abstract:
With the emergence of multidrug-resistant mycobacterial strains, better therapeutic strategies are required for the successful treatment of the infection. Although antimicrobial peptides (AMPs) and silver nanoparticles (AgNPs) are becoming one of the popular antibacterial agents, their antimycobacterial potential is not fully evaluated. In this study, we synthesized biogenic-silver nanoparticles using bacterial, fungal, and plant biomasses and analyzed their antibacterial activities in combination with AMPs against mycobacteria. Mycobacterium smegmatis was found to be more susceptible to AgNPs compared to M. marinum. We found that NK-2 showed enhanced killing effect with NP-1 and NP-2 biogenic nanoparticles at a 0.5-ppm concentration, whereas LLKKK-18 showed antibacterial activity only with NP-2 at 0.5-ppm dose against M. smegmatis. In case of M. marinum NK-2 did not show any additive activity with NP-1 and NP-2 and LLKKK-18 alone completely inhibited the bacterial growth. Both NP-1 and NP-2 also showed increased killing of M. smegmatis in combination with the antituberculosis drug rifampin. The sizes and shapes of the AgNPs were determined by transmission electron microscopy and dynamic light scattering. AgNPs showed no cytotoxic or DNA damage effects on macrophages at the mycobactericidal dose, whereas treatment with higher doses of AgNPs caused toxicity and micronuclei formation in cytokinesis blocked cells. Macrophages actively endocytosed fluorescein isothiocyanate-labeled AgNPs resulting in nitric oxide independent intracellular killing of M. smegmatis. Apoptosis and cell cycle studies showed that treatment with higher dose of AgNPs arrested macrophages at the G1-phase. In summary, our data suggest the combined effect of biogenic-AgNPs and antimicrobial peptides as a promising antimycobacterial template.
Insights
Biogenic silver nanoparticles combined with antimicrobial peptides show promise for treating drug-resistant mycobacteria. This combination enhances killing effects against Mycobacterium smegmatis and Mycobacterium marinum, offering a new therapeutic strategy.
Area of Science:
- Biotechnology
- Nanomedicine
- Microbiology
Background:
- Multidrug-resistant mycobacteria necessitate novel therapeutic approaches.
- Antimicrobial peptides (AMPs) and silver nanoparticles (AgNPs) show antibacterial potential but require further evaluation against mycobacteria.
- Biogenic synthesis of AgNPs offers a sustainable method for nanoparticle production.
Purpose of the Study:
- To synthesize biogenic AgNPs using various biomasses.
- To evaluate the antimycobacterial activity of AgNPs alone and in combination with AMPs against Mycobacterium smegmatis and Mycobacterium marinum.
- To assess the safety and cellular interactions of AgNPs with macrophages.
Main Methods:
- Synthesis of AgNPs using bacterial, fungal, and plant biomass.
- Antimicrobial susceptibility testing of AgNPs and AMPs against M. smegmatis and M. marinum.
- Characterization of AgNPs using transmission electron microscopy and dynamic light scattering.
- Cytotoxicity assays, DNA damage assessment, and apoptosis studies on macrophages.
- Intracellular killing assays using fluorescein isothiocyanate-labeled AgNPs.
Main Results:
- Biogenic AgNPs demonstrated varying susceptibility against M. smegmatis and M. marinum.
- Specific AMPs (NK-2, LLKKK-18) showed enhanced antimycobacterial activity when combined with certain AgNPs (NP-1, NP-2) at 0.5 ppm.
- AgNPs combined with rifampin increased the killing of M. smegmatis.
- AgNPs exhibited no cytotoxicity or DNA damage at mycobactericidal doses but showed toxicity at higher concentrations.
- Macrophages actively internalized AgNPs, leading to nitric oxide-independent intracellular killing of M. smegmatis.
- Higher AgNP doses induced G1-phase arrest in macrophages.
Conclusions:
- Biogenic AgNPs combined with AMPs represent a promising strategy against mycobacterial infections.
- The synergistic effects observed suggest potential for developing novel antimycobacterial therapies.
- AgNPs demonstrate a favorable safety profile at therapeutic concentrations, with macrophages playing a key role in intracellular pathogen clearance.
Related Concept Videos
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Biological Methods for Microbial Control
Defense Against Bacterial Pathogens
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
Inhibitors of Bacterial Protein Synthesis
Antimicrobial Effectiveness
Clinical Significance of Antibiotic Resistance


